Central nervous system (CNS) delivery of anti-inflammatory cytokines, such as interleukin 4 (IL4), holds promise as treatment for multiple sclerosis (MS). We have previously shown that short-term herpes simplex virus type 1-mediated IL4 gene therapy is able to inhibit experimental autoimmune encephalomyelitis (EAE), an animal model of MS, in mice and non-human primates. Here, we show that a single administration of an IL4-expressing helper-dependent adenoviral vector (HD-Ad) into the cerebrospinal fluid (CSF) circulation of immunocompetent mice allows persistent transduction of neuroepithelial cells and long-term (up to 5 months) CNS transgene expression without toxicity.
Introduction
Multifocal and chronic inflammatory disorders of the central nervous system (CNS), such as multiple sclerosis (MS), might benefit from gene therapy based on the use of viral vectors expressing anti-inflammatory molecules. However, gene therapy using viral vectors as carriers of therapeutic molecules is of limited therapeutic efficacy due to several constrains. 1 Viral vectors do not reach the CNS upon systemic injection owing to the presence of the blood-brain barrier. 2 The direct injection of viral vectors into the brain parenchyma allows only a restricted diffusion-few centimeters away from the injection site-of viral particles and large molecules (except for proteins actively transported by neurons). 3, 4 Systemic as well as intraparenchymal delivery of viral vectors usually induces humoral and cell-mediated immune responses against the vectors and/or transgene products, leading to inflammation, short-term persistence of gene expression and elimination of transduced cells. [5] [6] [7] We, and others, have previously shown that injection of viral vectors into the cisterna magna, or trough lumbar puncture, might represent an efficient CNS delivery system in both small (mice) and large (non-human primates) animals. [8] [9] [10] [11] Administration of vector into the cerebrospinal fluid (CSF) circulation, while bypassing the blood-brain barrier, allows viral vector transduction of neuroepithelial cells and delivery of transgene products to the whole CNS through the ventricular circulation. However, viral vector delivery via the CSF circulation still does not represent a realistic gene therapy option for chronic CNS disorders because of the short-term expression and residual immunogenicity of the vectors so far tested (for example, first-generation herpes simplex virus type 1-derived vectors or first generation Ad vectors). 10, 12 We have now established a long-lasting and nontoxic cytokine delivery system, both in mice and monkeys, based on the intrathecal administration of an interleukin 4 (IL4)-producing helper-dependent adenoviral vector (HD-Ad). We have shown evidence of the clinical, neuropathological and neurophysiological efficacy of this therapy in mice affected with chronic or relapsingremitting experimental autoimmune encephalomyelitis (EAE), modeling the most common clinical subtypes of MS. Finally, we demonstrate that the protective mechanism induced by IL4 gene therapy in EAE is mediated, at least partially, by an increased recruitment of CD25 + Foxp3 + T regulatory (Treg) cells to the CNS.
Results
Whole-CNS distribution and long-term transgene expression following intracisternal administration of an HD-Ad vector in C57Bl/6 mice CNS distribution and persistence of HD-Ad vectors injected into the CSF were analyzed in 25 C57Bl/6 mice. A single injection of 10 7 t.u. (B5 Â 10 8 t.u. kg
À1
) of an STK-120-derived HD-Ad vector-expressing green fluorescent protein (GFP) and murine IL4 under independent transcriptional control (hereafter referred as Ad-G/IL4 vector)-was administered into the cisterna magna of each mouse. The Ad-G/IL4 vector spread through the entire mouse brain ventricular system (Figures 1a and b) , and efficiently transduced leptomeningeal cells on the external, especially basal, surface of the brain (Figure 1c) , and cells from the ependyma and choroid plexuses along the inner ventricular spaces (Figure 1d ). No GFP signal was detected within the CNS parenchyma in all mice evaluated (Figures 1c and d) . Biodistribution of Ad-G/ IL4 was further analyzed by PCR in the DNA obtained from different tissues and organs from injected mice. PCR analysis showed that the number of vector genomes in the CNS declined steadily in the first month, and persisted at a stable level of approximately 5 Â 10 3 copies mg
of DNA up to 5 months after injection (Figure 1h ). Outside the CNS, approximately 10 3 copies mg À1 of DNA were detected, 1 month after injection, only in the kidney and intestine (Supplementary Figure 1) . Transgenes expression was then analyzed. In situ hybridization showed that cells facing liquoral spaces were strongly positive for GFP mRNA (Figure 1e ). To exclude possible transcription of endogenous IL4 mRNA, we set up an RT-PCR assay specific for the exogenous adenoviral IL4 expression cassette and confirmed that only IL4 gene therapy-treated mice were positive (Figure 1f) . Finally, synthesis of up to 350 pg ml À1 of murine IL4 was detected in the CSF, by a fluorescent ELISA, throughout the entire observational period. Despite that fact that the very low amounts of CSF available for analysis (1-3 ml per mouse) might lead to underestimation, detectable levels of IL4 persisted up to 5 months after injection (Figure 1g ), further supporting long-term CNS persistence of the vector. The level of IL4 in the serum remained below 15 pg ml À1 in all mice throughout the analyzed period (data not shown).
Intracisternal delivery of Ad-G/IL4 induces clinical and functional recovery from chronic progressive EAE
We then studied the therapeutic potential of Ad-G/IL4-mediated gene therapy in a chronic-progressive model of EAE (C-EAE). C-EAE was induced in C57Bl/6 mice by immunization with MOG 35À55 , as described previously. 13 The Ad-G/IL4 vector was injected intracisternally at a dose of 10 7 t.u. per mouse on the day of disease onset, occurring between days 10 and 19 post-immunization. Control mice were injected with an HD-Ad vector expressing only GFP (Ad-G vector). Administration of the Ad-G/IL4 vector significantly decreased the disease burden, as measured by the average (Figure 2a ) and cumulative clinical disease scores (Table 1) between days 30 and 70. Treatment with Ad-G/IL4 significantly improved also the neurophysiological parameters. Motor-evoked potentials (MEP)-used as a functional measure of corticospinal tract integrity 14 -were measured in C-EAE mice at 75 days post-immunization. MEP was recordable in 10/11 (91%) of the Ad-G/IL4-treated mice but in only 5/10 (50%) of the control, Ad-Gtreated mice (Po0.05, w 2 ). Central conduction time (CCT) averaged 3.0±0.4 ms in Ad-G/IL4-treated mice (reference value in healthy mice: 2.8 ± 0.3) vs 3.3 ± 0.5 ms in control, Ad-G-treated mice (P ¼ 0.02, Mann-Whitney) (Figure 2b ). Figure 3 ). Neuropathological features were accompanied by an increase of T-cells (CD3 + ) infiltrating the CNS (Table 1 ). This finding was not due to the alteration in peripheral antigen-driven T-cell expansion, as T-cell proliferation (Figure 4a -regulatory T-cell fraction-known to have suppressant activity during autoimmune reactions 15 decreased in the spleen and peripheral circulation, whereas increased in draining lymph nodes and in the CNS at the peak of disease, 14-21 days after immunization (Figure 5a ). In all mice treated with the Ad-G/IL4 vector affected by either C-EAE, the percentage and absolute number of CD4 + CD25 + Foxp3 + T cells significantly increased in the CNS 21 days after immunization compared to mice treated with the control Ad-G vector (Figures 5b-c) . In addition, mRNA levels of foxp-3, a transcription factor specifically expressed in CD25 + -regulatory T cells, 15 were significantly increased in the brain and spinal cords of C-EAE mice treated with the Ad-G/IL4 vector as compared to control mice (Figure 5d ). When we compared CD25 + -regulatory T cells from IL4-treated mice and controls, purified from draining lymph nodes at the peak of disease, we found similar suppressive ability in an in vitro assay (Figure 5e Figure 2a) . On the contrary, the percentage of Annexin V + , propidium iodide À cells increased in both the CD4 + and CD8 + T-cell fraction in Ad-G/IL4-treated mice (Supplementary Figure  2b) . Taken together, these results indicate that vectormediated IL4 release within the CSF circulation promotes the recruitment within inflamed CNS areas of regulatory T cells, which, in turn, induce apoptosis rather than anergy of CNS-infiltrating encephalitogenic T cells. 
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IL4 gene therapy increases the recruitment of Treg cells by increasing the synthesis of chemo-attractant cytokines in inflamed CNS areas
To understand the mechanism(s) underlying the increased recruitment of Treg cells in the CNS of Ad-G/ IL4-treated mice, we measured mRNA levels of chemokines known to attract CD4
-regulatory T cells in the CNS of treated and control mice, 24 days after immunization. 16 As shown in Figures 6a-c, CCL1, CCL17 and CCL22 mRNA levels were significantly increased (Po0.05) in the brain and spinal cord of C57BL/6 mice affected by C-EAE and treated with Ad-G/IL4 compared to control mice. It has been previously shown that CCL1 and CCL22 are expressed in EAE lesions. 17 We then investigated which cell subpopulation is able to release these chemokines during CNS inflammation, and found that BV.2, a murine microglial cell line, secretes CCL22 when stimulated with pro-inflammatory cytokines ( Figure 6d ). The amount of CCL22 released by stimulated BV.2 was significantly increased, in a dose-dependent way, by the addition of IL4 (Figure 6d) . By confocal microscopy, we were able to colocalize CCL17 + cells and inflammatory cell (Figure 6e ) and endothelial ( Figure 6f ) markers. We also measured the levels of three mast-cellspecific markers in the CNS of Ad-G/IL4-and Ad-Gtreated mice, as there are data indicating that CCL1 is mostly released by mast cells 18 and that mast cells are involved in CD4 + CD69
À CD25 + -regulatory T cells function. 19 No significant difference in mRNA of mast cell markers were observed between treated and control mice (Supplementary Figure 3) . Our data suggest that Ad-G/IL4 treatment increases the synthesis of chemo-attractant chemokines in the CNS, supporting, in turn, the increased recruitment of Treg cells to the neuroinflammatory lesions.
Intracisternal delivery of Ad-G/IL4 induces clinical and functional recovery from relapsing EAE
To verify whether IL4 gene therapy is able to interfere also with relapsing EAE (R-EAE), modeling the most common clinical form of human MS, using the same Treg-mediated mechanism, we immunized SJL mice with PLP139-151. Indeed, after intracisternal injection of Ad-G/IL4 on the day of disease onset, occurring between days 12 and 16 post-immunization, we again observed decreased average (Figure 7a ) and cumulative clinical disease scores (Table 1) between days 40 and 102 postimmunization. Furthermore, a significant decrease in the rate and severity of relapses was observed in R-EAE mice as compared to Ad-G-treated control mice (Table 1) . Accordingly, we found improved neurophysiological parameters in IL4-treated R-EAE mice: resting motor threshold (cMEP threshold) was restored after Ad-G/IL4 treatment (11.2 ± 5.6 vs 30.9 ± 11.7 mA in control mice, normal range: 3-15 mA) (Figure 7b ). Finally, IL4-treated R-EAE mice exhibit increased percentage of CD4CD25+CD69À Treg cells and of foxp3 mRNA, compared to Ad-G-treated R-EAE mice, thus suggesting a similar effect of exogenous IL4 delivery in both EAE models tested (Figures 7c-d) .
Discussion
To prove the therapeutic value of intra-CSF gene therapy, we administered intratechally an IL4-producing HD-Ad vector into mice affected by either chronic-progressive or relapsing-remitting EAE, two autoimmune demyelinating disorders reproducing some of the pathological features of human MS. Administration of the vector after disease onset induced significant clinical and functional recovery in both models. The neurophysiological parameters used as a measure of myelin and axonal integrity are similar to those used in human MS patients. Interestingly, IL4 reduced demyelination and axonal loss in EAE mice, while increasing rather than reducing the number of CNS-infiltrating T cells. A similar phenomenon was previously observed in relapsing-remitting EAE induced in Biozzi AB/H after treatment with an IL4-expressing herpes simplex virus type 1-derived vector. 20 We now show that the increased T-cell 
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CD25
+ T cell recruitment to the CNS? It has previously been reported that CD25
+ Treg cells express preferentially CCR4 and CCR8 chemokine receptors, and migrate in response to chemokines CCL1, CCL17, CCL22, 16, 23, 24 and more recently it has been shown that CCR4 plays a pivotal role in tissue-specific homing of Treg cells. 25 We found that synthesis of CCL1, CCL17 and CCL22 is increased in the CNS by IL4 gene therapy. It is known that IL4 is able to induce CCL17 and CCL22 in mononuclear cells. 18 Furthermore, it had previously shown that microglial cells express CCL22 during EAE. 26 Here, we show that microglial cells are stimulated by IL4 to significantly increase the release of CCL22 during inflammation, thus supporting the idea that IL4 increases CD25 + Treg cells recruitment. We also show that CCL17 is expressed by endothelial cells and infiltrating T cells during EAE, although we have no evidence, other than the increase of CCL17 mRNA, of a direct or indirect effect of IL4 on these cells. Thus, engagement by CCL17 and CCL22 of the CCR4 receptor expressed on CD4 
+ T cells are protective when passively transferred to EAE mice, 27 ,28 and we show here that CD4 + CD25 + T cells from IL4-treated mice retain their suppressive ability. IL4 is a pleiotropic cytokine and we have described, in the past, additional mechanisms mediating the beneficial effect of IL4 gene therapy. 10 As, however, Treg cell-based therapy is difficult to conceive in practical terms, due to difficulties in ex vivo cell manipulation and delivery, induction of CD4 + CD69
À CD25 + T cell migration to the CNS by administration of a cytokine such as IL4 may be a feasible and promising therapeutic option. We show that the combination of an HD-Ad vector to deliver IL4 and a delivery confined to the CSF induces a sustained and effective recruitment of Treg cells with little side effects.
In conclusion, we provide preclinical evidence of the safety and efficacy of intrathecal HD-Ad-vectormediated gene therapy in mice modeling the two most common clinical forms of human MS. Furthermore, we describe that IL4-mediated recruitment of Treg cells is Mann-Whitney nonparametric test.
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E Butti et al (g-j) Demyelination (Kluver-Barrera) (g and h) and axonal loss (Bielshowsky) (i and j) are predominant in the control mouse (h and j), as compared to the IL4-treated mouse (g and i). All panels shown are Â 20. EAE, experimental autoimmune encephalomyelitis.
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the major mechanism suppressing CNS autoimmunity, providing a rationale to further explore the feasibility of this gene therapy approach to human autoimmune demyelinating disorders, such as MS and acute disseminated encephalomyelitis.
Materials and methods
Animals
Six-to eight-week-old C57Bl/6 and SJL female mice were obtained from Charles River (Calco, Italy), and housed in specific pathogen-free conditions. All procedures involving animals were performed according to the guidelines of the Institutional Animal Care and Use Committee of the San Raffaele Scientific Institute.
Vector construction and production
Two helper-dependent adenoviral vectors were generated in the context of the STK-120 vector backbone: 29 the Ad-G/IL4 vector carried the expression cassettes for murine IL4 and the GFP cDNAs, respectively, driven by the phosphoglycerokinase and the cytomegalovirus immediate-early promoter; the Ad-G control vector contained only the cytomegalovirus-GFP expression cassette. Viral stocks were obtained and titrated as , purified from draining lymph nodes at the peak of disease, are equally able to suppress proliferation of effector T cells as those taken from control EAE mice (closed dots). EAE, experimental autoimmune encephalomyelitis. 30 Primers specific for the HD-Ad backbone were designed to detect viral genomes in the animal tissues.
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EAE induction and vector administration
Chronic progressive EAE (C-EAE) was induced in C57Bl/6 mice by immunization with 50 mg per mouse of MOG 35À55 (Espikem, Florence, Italy), and two injections of 500 ng pertussis toxin the day of immunization and 48 h later. Relapsing-remitting EAE (R-EAE) was induced in SJL mice by two immunizations, 7 days apart, with 200 mg per mouse of PLP 139À151 (Espikem, Florence, Italy), and four injections of 500 ng pertussis toxin on the day of immunization and 48 h later. Weight and clinical score (0 ¼ healthy, 1 ¼ flaccid tail, 2 ¼ paresis of hindlimbs, 3 ¼ paralysis of hindlimbs and/or paresis of forelimbs, 4 ¼ tetraparalysis, 5 ¼ moribund or dead) were recorded daily. HD-Ad vectors were administered by injecting a single dose of 10 7 t.u in 10 ml of PBS in the cisterna magna the day of clinical onset of EAE, as described previously. 20 
Pathology, immunohistochemistry and immunofluorescence
Mice were transcardially perfused with saline followed by cold 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Spinal cords and brains were removed and either frozen or embedded in paraffin. To quantitate neurological damage in EAE mice, paraffin-embedded tissue sections were cut at 10 mm and stained with hematoxylin and eosin, Luxol fast Blue and Bielshowsky stain to detect inflammatory infiltrates, demyelination and axonal loss, respectively. T cells were stained using a rat anti-CD3 (pan-T-cell marker; Serotec Ltd, Oxford, UK) revealed with a biotin-labeled secondary anti-rat Ab (Amersham, Airlington Heights, IL, USA). Macrophages were stained with BS-I isolectin B4 (Sigma, St Louis, MO, USA) revealed with a biotin-labeled secondary anti-rat Ab (Amersham). Neuropathological findings were quantified on an average of 10 complete cross-sections of spinal cord per mouse. The number of perivascular inflammatory infiltrates was calculated and expressed as the numbers of inflammatory infiltrates per mm 2 , demyelinated areas and axonal loss were expressed as . For immunohistochemistry, 10-mmthick frozen sections were stained with rabbit polyclonal Abs specific for GFP (1:1500; Molecular Probes, Eugene, OR, USA), goat polyclonal Abs specific for CCL17 (1:100; Santa Cruz), rabbit polyclonal Abs specific for GFAP (1:700; Dako Spa, Milan, Italy), mouse monoclonal Abs specific for NeuN (1:1000; Chemicon, Temecula, CA, USA), rat monoclonal Abs specific for CD11b (1:100; Abcam, Cambridge, UK), rabbit polyclonal Abs specific for laminin (1:500; Sigma) and rat monoclonal Abs specific for CD45.1 (1:100; Pharmingen, BD Biosciences, Erembodegen, Belgium). In all experiments, appropriate secondary Abs were used and nuclei stained with DAPI (1:25 000; Roche Diagnostics Spa, Monza, Italy). Staining omitting the primary Abs were used as negative control.
Neurophysiology
Cortical motor-evoked potentials (cMEP) were recorded as described previously.
14 Anesthetized mice were placed under a heating lamp to avoid hypothermia. Cortical motor-evoked potentials (cMEP) were elicited by using a pair of monopolar needle electrodes placed over the intact scalp, with the tip of the stimulating cathode placed above the interaural line and the anode over the temporal bone. Muscle responses evoked by descending volleys through transynaptic depolarization of spinal a-motoneurons were recorded with a bipolar 'belly-tendon' montage: the active needle electrodes were inserted into hindlimb footpad muscles, while the references were placed under the skin of second digit. The electromyographic signal was bandpassed with 50 Hz-5 KHz filters and recorded with a Myohandy electromyographer (Micromed, Mogliano Veneto, Italy), with the sweep velocity settled at 20 ms and sensitivity at 200 mV. Spinal MEP was recorded at the lumbar level inserting a pair of stimulating needle electrodes closely to spinal emergency of sciatic nerve roots. cMEP latency-measured the time of electrical impulse propagation from motor cortex to hindlimb muscle-and spinal MEP latency-measured the time of electrical impulse propagation from the origin of motor roots to the muscle-were obtained. Difference between the above-described latencies is an index of propagation between motor cortex and spinal cord, namely CCT.
Exogenous IL4 PCR
Total brain RNA of control and IL4-treated mice was extracted and reverse transcribed using the ThermoScript RT-PCR System Kit (Invitrogen, Paisley, UK) and primers specific for 3H Histone, as house-keeping gene and specific for exogenous IL4 (5 0 gatgctctttaggctttcca3 0 ). PCR amplification for exogenous IL4 was then 
Semiquantitative real-time PCR
RNA samples from the whole brain parenchyma and spinal cord of mice were prepared by the RNAfast Kit (Molecular System). After retro-transcription by a commercially available kit (Ready-to-go, Pharmacia, Uppsala, Sweden), cDNAs and DNAs were amplified using specific commercially available primers (Pre-developed Taqman assays reagents, PDAR) on a 7700 Perkin Elmer thermocycler using the Taqman Kit (Applied Biosystems, Foster City, MA, USA). A threshold cycle was calculated and relative quantitation was obtained by comparison with the threshold cycle obtained by amplifying samples with glyceraldehyde-3-phosphate dehydrogenase-specific primers.
In situ hybridization for GFP Sections were post-fixed 15 min in 4% paraformaldehyde, then incubated in 0.5 mg ml À1 of proteinase K in 100 mM Tris-HCl, pH8, 50 mM EDTA for 10 min at 30 1C. Sections were incubated in 0.1 M triethanolamine (pH 8) for 5 min and then 400 ml of acetic anhydride were added two times for 5 min each. Hybridizations were done using aP33 riboprobes at the concentration ranging from 10 6 to 10 7 cpm per slides, overnight at 60 1C. The following day sections were incubated in ribonuclease-A (Roche) 20 mg ml À1 in 0.5 M NaCl, 10 mM Tris-HCl pH 8, 5 mM EDTA; 30 min at 37 1C. Sections were washed in formamide 50% SSC 2 Â for 30 min at 60 1C and then slides were rinsed two times in SSC 2 Â . Finally, slides were dried by using ethanol series. A 1 ml (Amersham) emulsion was applied in dark room, according to manufacturer's instructions. After 3 weeks, sections were developed in dark room, counterstained with Hoecsht; coverslipped with DPX (BDH) mounting solution. We used a GFP probe containing a 0.8 kb cDNA fragment.
Flow cytometry
Mononuclear cells purified on Percoll gradient from homogenized mouse brains and spinal cords were stained with CD4-APC, CD69-FITC and CD25-PerCP (Pharmingen), as described previously. 27 FITC-or PElabeled anti-Foxp3 (Pharmingen) was used according to manufacturer's instructions. Cytofluorimetric analysis was performed with a FACScanR flow cytometer (Becton Dickinson, Mountain View, CA, USA) equipped with CellQuest software. Events acquired are measured 50 000 per sample.
Proliferation assays
Spleen cells (4 Â 10 5 cells per well) were cultured in 96-well culture plates (Costar, Cambridge, MA, USA) in RPMI medium supplemented with 10% FCS, 2 mM L-glutamine (Sigma), and serial concentrations (1, 3, 10 mM) of the MOG 35-55 peptide or 0.1 mg ml À1 of anti-CD3 (for inhibition assays). Cultures were incubated for 3 days in 5% CO 2 . For in vitro assays, lymphocytes were grown as above, while BV.2 cells (kind gift from Francesca Aloisi) were grown in DMEM 10% FBS, supplemented with 2 mM glutamin and 100 U ml À1 penicillin/streptomycin, with or without 100 U ml À1 IL1b (Euroclone, Pero, Italy), 200 U ml À1 TNFa (Peprotech, Rocky Hill, NJ, USA), 500 U ml À1 IFNg (Becton Dickinson) (Th1 mix) and with the indicated amount of IL4 (R&D Systems). Supernatants were assayed after 24 h using a commercial ELISA kit from R&D systems for CCL22, following manufacturer's instructions.
